Benign prostatic hyperplasia (BPH) is one of the most common urinary diseases affecting men, generally after the age of 50. The prevalence of this multifactorial disease increases with age. With aging, the plasma level of testosterone decreases, as well as the testosterone/estrogen ratio, resulting in increased estrogen activity, which may facilitate the hyperplasia of the prostate cells. Another theory focuses on dihydrotestosterone (DHT) and the activity of the enzyme 5α-reductase, which converts testosterone to DHT. In older men, the activity of this enzyme increases, leading to a decreased testosterone/DHT ratio. DHT may promote prostate cell growth, resulting in hyperplasia. Some medicinal plants and their compounds act by modulating this enzyme, and have the above-mentioned targets. This review focuses on herbal drugs that are most widely used in the treatment of BPH, including pumpkin seed, willow herb, tomato, maritime pine bark, Pygeum africanum bark, rye pollen, saw palmetto fruit, and nettle root, highlighting the latest results of preclinical and clinical studies, as well as safety issues. In addition, the pharmaceutical care and other therapeutic options of BPH, including pharmacotherapy and surgical options, are discussed, summarizing and comparing the advantages and disadvantages of each therapy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8659259PMC
http://dx.doi.org/10.3390/molecules26237141DOI Listing

Publication Analysis

Top Keywords

benign prostatic
8
prostatic hyperplasia
8
activity enzyme
8
bph including
8
treatment benign
4
hyperplasia
4
hyperplasia natural
4
natural drugs
4
drugs benign
4
hyperplasia bph
4

Similar Publications

Introduction: Water vapor thermal therapy (WVTT; REZUM™; Boston, USA) offers symptom relief with reduced risks of complications in patients with lower urinary tract symptoms (LUTS) related to benign prostatic obstruction (BPO). WVTT therapy has been validated in the pivotal study in men with smaller prostates (< 80 cc). Yet, its feasibility for larger prostates (≥ 80 cc) remains underexplored.

View Article and Find Full Text PDF

Benign prostatic hyperplasia (BPH) is among the most common age-associated diseases in men; however, the contribution of age-related changes in immune cells to BPH is not clear. The current study determined that an age-associated CD8 T cell subset (Taa) with high Granzyme K ( ) and low Granzyme B ( ) gene expression infiltrate aged human prostates and positively correlate with International Prostate Symptom Score (IPSS). A velocity analysis indicated that CD8 T cell differentiation is altered in large BPH prostates compared to small age-matched prostates, favoring Taa accumulation.

View Article and Find Full Text PDF

Introduction And Aim:  Benign prostatic hyperplasia (BPH) is the enlargement and overgrowth of the prostate leading to the compression of the urethra and resulting in obstruction to the outflow of urine. Prostatic urethral lift (UroLift) is a budding minimally invasive technique that utilises mechanical manipulation of the prostate tissue so that the urethra is free from compression, thereby creating a channel for the outflow of urine. The aim of the audit was to assess the short- to medium-term outcomes in our centre in terms of improvement in symptoms, quality of life (QoL) and complication rates.

View Article and Find Full Text PDF

Hemostasis is a critical aspect of holmium laser enucleation of the prostate (HoLEP) for benign prostatic hyperplasia (BPH). While HoLEP offers superior outcomes compared to traditional techniques, effective intraoperative and postoperative bleeding control remains a challenge. This report evaluates the feasibility and safety of PuraBond® (3-D Matrix, Ltd.

View Article and Find Full Text PDF

Objective: This paper aims to evaluate the disparities in efficacy and safety across various oral Chinese patent medicines for the treatment of benign prostatic hyperplasia (BPH), using a frequency-based reticulated meta-analysis.

Methods: The researchers searched the following databases: Web of Science, PubMed, Excerpta Medical Database (Embase), Cochrane Library, China Knowledge Network (CNKI), China Biomedical Literature Service System (SinoMed), Wanfang Data Knowledge Service Platform and China Science and Technology Periodicals Database (VIP). Besides, the researchers collected all randomized controlled trials (RCTs) of oral Chinese patent medicines, as well as simple preparations and simple preparations for benign prostatic hyperplasia from the establishment of the database until July1, 2024.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!